Project Grant R43EB022016

Endoshape, Inc. was awarded a $370,938 project grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop radiopaque shape memory polymers for neurovascular embolotherapy applications. The Cardiovascular Diseases Research program aims to support heart and vascular research, including through competitive research training grants. Under this award, Endoshape will develop new radiopaque shape memory polymer materials incorporated into embolic coils....

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $299,518 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to V-Flow Medical Inc. to develop a novel diagnostic catheter and modular stent system to treat pelvic venous insufficiency (PVI), a primary cause of chronic pelvic pain (CPP) in women. The project will utilize an ovine model to evaluate the safety and efficacy of V-Flow's catheter and stent system in improving clinical outcomes...

This SBIR Phase I Project Grant, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program, is developing a novel minimally invasive procedure for deploying an implantable spinal cord stimulation (SCS) lead using a shape memory polymer (SMP). The $304,259 project, which runs from October 1, 2025 to June 30, 2026, aims to create an 8-channel SMP-based paddle lead that can be molded into a compact configuration for minimally...

This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,229 to Limax Biosciences Inc. to advance the development of their HEMOMAX biodegradable hydrogel sealant for use in vascular surgery. The key objectives are to: (1) conduct comprehensive bench performance testing, including sterilization validation and endotoxin assessment, and (2) evaluate the safety and efficacy of HEMOMAX in a...

This $274,547 Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a novel Aneurysm Sealing Device (ASD) for endovascular treatment of Abdominal Aortic Aneurysms (AAA). The project seeks to create a device that can completely seal the aneurysm sac, reducing the risk of post-procedure complications and the need for repeat interventions. Key objectives include validating the device's adaptability...

The U.S. National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,364,080 project grant to Vesteck, Inc. on September 15, 2025. The grant supports the development and feasibility testing of Vesteck's novel endovascular suturing device for augmenting endograft fixation during endovascular repair of abdominal aortic aneurysms (AAAs). The device aims to reduce reinterventions due to endograft migration or type 1A...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $496,255 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivita Technologies, Inc. (Davis, CA) to validate its patented SPEAR Platform™ technology for developing unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements. The project aims to produce BARE™ patches derived from porcine pericardium that can avoid immune rejection, integrate with...

Venarum Medical LLC received a $255,619 Project Grant award from the National Science Foundation on August 15, 2021 to support research and development activities concluding on May 31, 2022. The funding was provided through the NSF's Engineering program (CFDA #47.041), which aims to improve quality of life and economic strength through engineering innovation and excellence. Specifically, the grant supports Venarum Medical's "SBIR PHASE I: INTEGRATED MANUFACTURING OF ARTIFICIAL VALVES FOR...

The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research grant program (CFDA 93.837), awarded $1,032,585 to Aveera Medical Inc. on September 1, 2025. The funding supports Aveera Medical's project to develop and evaluate their novel Native Deep Vein Arterialization (NDVA) procedure using the Boomerang System. This technology aims to reduce major amputations and improve quality of life for patients with "no-option" chronic limb-threatening...

This $1,082,412 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research and development of tissue-engineered vascular grafts (TEVGs) using mesenchymal stem/stromal cells (MSCs) and extracellular vesicles (EVs). The University of Pittsburgh, the awardee, aims to optimize their silk scaffold-based TEVG construct seeded with EVs to advance it towards clinical translation. Key objectives include conducting in vitro...